Ann: BENITEC ABSTRACT ACCEPTED FOR AASLD MEETING, page-12

seanl,

my (linited) understanding is that there are three stages to the treatment:

1) delivering TT-304 to liver cells using a viral vector,
2) TT-304 then generating the anti-HCV shRNAs designed to fight HCV and
3) those shRNAs actually reducing or eliminating HCV virus

This abstract tells us:

1) yes - the viral vector is working very well - TT-304 is getting into plenty of liver cells (we already knew this was the case, at least to some extent)

2) yes - shRNA are indeed being generated - I think this is new and very big news

3) don't know - impact on HCV virus is still unknown, at least to us.


So, two steps down, last one to come. But in many ways, the first two steps may have been more major hurdles than the last one.

GLTA